Abbott Diabetes Care Inc. v. Dexcom, Inc.

This patent infringement litigation, Abbott Diabetes Care Inc. v. Dexcom, Inc., involved two major operating companies in the highly competitive continuous glucose monitoring (CGM) device market. Plaintiff Abbott Diabetes Care Inc., a division of the global healthcare company Abbott Laboratories, develops and manufactures glucose monitoring devices and systems. Defendant Dexcom, Inc. is an American multinational healthcare company specializing in the development, manufacturing, and distribution of its own line of CGM systems for diabetes management. The accused products in this dispute were Dexcom's continuous glucose monitoring devices, such as the Dexcom G6 and G7 systems, which directly compete with Abbott's offerings like the FreeStyle Libre series. The litigation concerned U.S. Patent 8,613,703, titled "Analyte sensor," which generally describes improved glucose sensing technology.

The case was filed in the United States District Court for the District of Delaware under case number 1:19-cv-01777 and was presided over by Judge Maryellen Noreika. The District of Delaware is a significant venue for patent litigation, consistently ranking among the busiest courts for such cases and being a top choice for operating company patent disputes. This venue is frequently selected due to its specialized patent bar, judges experienced in complex intellectual property matters, and established local patent rules.

This litigation was notable as part of an extensive, global patent battle between two dominant players in the continuous glucose monitoring industry. The dispute in Delaware was a consolidation of U.S. actions that commenced after a prior 2014 cross-license agreement and an associated covenant not to sue expired in March 2021. Dexcom initially filed suit in the Western District of Texas, prompting Abbott to countersue, with the U.S. aspects of their dispute eventually centralized in Delaware. The case's termination in December 2024 via a "zero-zero" settlement — meaning no financial payments from either company — was a significant outcome, establishing a 10-year "patent peace" between the rivals over their CGM products and resolving all outstanding global patent, trade dress, and design rights disputes. This settlement underscored the intense competition and strategic importance of intellectual property in the rapidly expanding CGM market.

Abbott Diabetes Care Inc. v. Dexcom, Inc., case number 1:19-cv-01777, filed in the United States District Court for the District of Delaware on September 20, 2019, involved US patent 8613703 and was ultimately terminated due to a settlement.

Due to the limited public docket information available through general web searches for this specific case (1:19-cv-01777), precise details regarding many specific legal developments are not readily accessible. The publicly available legal news and analyses predominantly cover a later and more complex series of litigations between Abbott and Dexcom that arose after a 2014 settlement agreement's covenant not to sue expired in March 2021. That later litigation, which involved Dexcom suing Abbott, Abbott filing breach of contract counterclaims, and Abbott challenging Dexcom's patents at the PTAB, was largely consolidated in the District of Delaware and culminated in a jury verdict in March 2024, followed by a global settlement.

Here's what can be stated about case 1:19-cv-01777:

• Filing & Initial Pleadings:

  • Complaint: Abbott Diabetes Care Inc. filed its complaint against Dexcom, Inc. on September 20, 2019, in the District of Delaware, asserting infringement of US patent 8613703. Specific details of the initial allegations beyond the patent at issue are not publicly detailed in the available search results.
  • Answer/Counterclaims: Details regarding Dexcom's answer or any counterclaims filed specifically within this 2019 case (1:19-cv-01777) are not available from the search results.

• Pre-trial Motions of Substance:

  • No specific pre-trial motions (e.g., motions to dismiss, transfer, stay pending IPR, or summary judgment) related to this particular 2019 case and patent 8613703 are detailed in the available search results. These types of motions were heavily reported in the later consolidated litigation between the parties, particularly regarding Abbott's efforts to transfer Dexcom's Texas-filed infringement suit to Delaware and Dexcom's attempt to enjoin Abbott's IPR filings.

• Claim Construction (Markman) Outcomes:

  • There is no indication in the search results that this specific 2019 case reached the claim construction (Markman) stage or that a Markman order was issued before its termination.

• Discovery Milestones with Strategic Significance:

  • No specific discovery milestones for this particular 2019 case are publicly detailed in the available search results.

• Trial Events, Verdict, and Post-trial Motions:

  • Given the case status "Terminated (Settled)," this specific case did not proceed to trial, verdict, or post-trial motions. A jury verdict did occur in a related, later consolidated Delaware litigation between the parties on March 22, 2024, finding Dexcom infringed one patent, cleared it of two, and was hung on another.

• Settlement, Dismissal, Judgment, or Appeal — the Final Disposition:

  • The case 1:19-cv-01777 was "Terminated (Settled)." The exact date of settlement and dismissal for this specific 2019 case is not explicitly stated in the provided search results. However, Abbott and Dexcom eventually entered a global settlement, described as a "10-year zero-zero patent peace over glucose monitoring devices," which resolved multiple ongoing litigations across various jurisdictions, including the District of Delaware, by December 2024. While the 2019 case was settled earlier, it's possible its resolution was part of a broader, long-term strategic peace or was settled in anticipation of such.

• Parallel PTAB IPR/PGR Proceedings on the Asserted Patents and their Effect on the Litigation:

  • The available search results extensively discuss multiple inter partes review (IPR) petitions filed by Abbott against Dexcom's patents in April 2022, and two IPRs filed by Dexcom against Abbott in February 2022, in the context of the later, broader litigation. However, there is no information in the search results indicating that Dexcom initiated any IPR or PGR proceedings specifically against Abbott's patent US 8613703 (the patent at issue in 1:19-cv-01777). The IPRs detailed in the search results concerned Dexcom's patents which were challenged by Abbott, and Dexcom's unsuccessful efforts to enjoin those IPRs based on a forum selection clause in a prior settlement agreement. Therefore, there is no evidence from the search results that parallel PTAB proceedings directly affected case 1:19-cv-01777 regarding patent 8613703.

Abbott Diabetes Care Inc. was represented by Kirkland & Ellis LLP as lead counsel, with several partners of the firm actively involved. Additionally, in-house counsel from Abbott Laboratories also played a role in the litigation. No separate local counsel firm was explicitly identified in the available information, suggesting that lead counsel handled local requirements or that specific Delaware-based attorneys within Kirkland & Ellis fulfilled this role.

Counsel of Record for Plaintiff Abbott Diabetes Care Inc.:

From Kirkland & Ellis LLP (Lead Counsel):

• Jason M. Wilcox - Partner
  • Firm and office: Kirkland & Ellis LLP, Washington, D.C.
  • Experience: Mr. Wilcox's practice focuses on intellectual property disputes, with notable experience in complex patent litigation, including achieving a precedent-setting victory for Abbott in a global dispute against a primary competitor before the Federal Circuit, which affirmed the denial of a preliminary injunction and allowed Abbott to file IPRs challenging DexCom's patents.
• William H. Burgess - Partner
  • Firm and office: Kirkland & Ellis LLP, Washington, D.C.
  • Experience: Mr. Burgess focuses on appellate litigation, including patent litigation, and has argued appeals in most U.S. courts of appeals, including several in the Federal Circuit.
• John C. O'Quinn - Partner
  • Firm and office: Kirkland & Ellis LLP, Washington, D.C.
  • Experience: Mr. O'Quinn's practice includes intellectual property litigation at both trial and appellate levels, and he has argued over fifty patent appeals in the U.S. Court of Appeals for the Federal Circuit.
• Amanda J. Hollis - Partner
  • Firm and office: Kirkland & Ellis LLP, Chicago, IL.
  • Experience: Ms. Hollis is an intellectual property litigator who has tried and led patent cases in federal courts across the country and before the United States International Trade Commission, representing clients such as Abbott Laboratories in high-stakes patent disputes.
• Benjamin Adam Lasky - Partner
  • Firm and office: Kirkland & Ellis LLP, New York, NY.
  • Experience: Mr. Lasky's practice is centered on patent litigation, with extensive experience in diverse technological fields including medical devices, and he also has considerable experience before the Patent Trial and Appeal Board.
• Ashley Ross - Partner
  • Firm and office: Kirkland & Ellis LLP, New York, NY.
  • Experience: Ms. Ross is an intellectual property partner focusing on patent and trade secrets litigation, routinely working on life sciences and high-tech patent cases, and has been an integral part of multiple district court and ITC trial teams.
• Ellisen Shelton Turner - Partner
  • Firm and office: Kirkland & Ellis LLP, Los Angeles, CA.
  • Experience: Mr. Turner serves as lead trial counsel on major patent and trade secret matters, and he has a sophisticated understanding of the high-tech sector, concentrating his practice on media and entertainment technology, software, telecom, semiconductor, biotechnology, and life sciences matters.

In-House Counsel for Plaintiff Abbott Diabetes Care Inc. / Abbott Laboratories:

• Rachel Bach - Divisional Vice President and Associate General Counsel, IP Diagnostics, Nutrition, and Trademarks
  • Firm and office: Abbott Laboratories (in-house).
  • Experience: Ms. Bach oversees IP diagnostics, nutrition, and trademarks for Abbott, with extensive experience in intellectual property litigation, primarily complex patent cases, and previously worked at Kirkland & Ellis LLP.
• Gael Tisack - Chief IP Counsel, Divisional Vice President & Associate General Counsel
  • Firm and office: Abbott Laboratories (in-house), Northbrook, IL.
  • Experience: Ms. Tisack leads a worldwide team of IP attorneys supporting the operating divisions at Abbott Laboratories, with her role including shaping and developing the IP department and protecting the company's strategic market position, and she has extensive experience managing all aspects of litigation.

While Scott C. Weidenfeller of Covington & Burling LLP was mentioned as lead counsel for Abbott Diabetes Care Inc. in Inter Partes Review (IPR) proceedings, the provided information does not explicitly confirm his role as counsel of record for the specific district court case 1:19-cv-01777. The focus for the district court case appears to be primarily with Kirkland & Ellis LLP.

Dexcom, Inc. was represented by counsel from Quinn Emanuel Urquhart & Sullivan, LLP, as well as by in-house legal counsel.

Here is a breakdown of the identified counsel:

External Counsel

• Jared W. Newton
  • Role: Lead Counsel
  • Firm: Quinn Emanuel Urquhart & Sullivan, LLP
  • Office Location: Wilmington, Delaware, and Washington, D.C.
  • Note: Jared Newton leads Quinn Emanuel's intellectual property practice in Delaware and handles all manner of patent, trademark, copyright, and trade secret disputes before the United States District Court for the District of Delaware. He is a former United States Patent Examiner and has taken numerous patent cases to trial, including representing Waymo against Uber in a landmark trade secret trial.
• Michael A. Barlow
  • Role: Counsel (Partner)
  • Firm: Quinn Emanuel Urquhart & Sullivan, LLP
  • Office Location: Wilmington, Delaware
  • Note: Michael Barlow is a partner in Quinn Emanuel's Wilmington office and is noted for his extensive experience and deep roots in Delaware, intimately familiar with the Delaware courts. Quinn Emanuel was relied upon by Dexcom for the U.S. portion of the multi-jurisdictional litigation against Abbott, which was consolidated in the District of Delaware.

In-House Counsel

While specific docket entries for this particular case were not directly accessible to confirm individual in-house appearances, it is standard practice for in-house counsel to support external litigation. Based on other patent litigation involving Dexcom around the same time and current roles, the following individuals are likely to have been involved:

• Kaare Larson
  • Role: In-house Counsel (likely Sr. Counsel/Director level at the time)
  • Firm: Dexcom, Inc.
  • Office Location: San Diego, California (Dexcom's headquarters)
  • Note: Kaare Larson was identified as in-house counsel for Dexcom in a 2019 patent case in the District of Oregon, indicating involvement in Dexcom's patent litigation matters.
• Kellin Chatfield
  • Role: In-house Counsel (likely Sr. Counsel/Director level at the time)
  • Firm: Dexcom, Inc.
  • Office Location: San Diego, California
  • Note: Kellin Chatfield was also identified as in-house counsel for Dexcom in a 2019 patent case in the District of Oregon, suggesting involvement in patent litigation.
• Paul Lee
  • Role: In-house Counsel (likely Sr. Counsel/Director level at the time)
  • Firm: Dexcom, Inc.
  • Office Location: San Diego, California
  • Note: Paul Lee was identified as in-house counsel for Dexcom in a 2019 patent case in the District of Oregon. Current job descriptions for IP Legal Counsel at Dexcom indicate responsibility for supporting global IP litigation activities.